Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Tute Genomics Platform Selected to Provide Clinical Interpretation for NextStepDx PLUS

Published: Saturday, July 12, 2014
Last Updated: Saturday, July 12, 2014
Bookmark and Share
Genetic testing service designed to detect genetic variants linked to autism spectrum disorders and other disorders of childhood development.

Tute Genomics has announced an agreement with Lineagen, Inc., to provide next-generation sequencing (NGS) analytics for Lineagen’s NextStepDx PLUS. Lineagen, focused on the diagnostic evaluation of neurodevelopmental and neurological disorders, currently offers FirstStepDx PLUS, a customized chromosomal microarray (CMA) testing service used by healthcare providers as a first-line genetic diagnostic test for individuals with developmental delay (DD), autism spectrum disorders (ASD) and other disorders of childhood development.

Later this year, the Company anticipates launching NextStepDx PLUS, a next-generation sequence-based test that is specifically designed to increase the clinical detection of single nucleotide genetic variants linked to ASD and other disorders of childhood development. ASD is the fastest-growing neurodevelopmental disability in the U.S., affecting approximately 1 in 88 children, including up to 1 in 58 boys.

“Tute Genomics’ NGS analysis platform can rapidly and accurately analyze complex whole exome data and generate customized clinical reports, and we are very pleased to partner with Tute as we prepare to launch NextStepDx PLUS later this year,” commented Michael Paul, Ph.D., CEO of Lineagen.

Paul continued, “Our new test identifies previously unknown genetic variants that confer a genetic risk of developing ASD, which Lineagen validated along with The Children’s Hospital of Philadelphia and the University of Utah. Together, Lineagen’s FirstStepDx PLUS and NextStepDx PLUS genetic testing service are expected to deliver the highest clinical detection rate clinically available for ASD and other disorders of childhood development.”

Reid Robison, M.D., M.B.A., CEO of Tute Genomics, said, “This new partnership between Lineagen and Tute will accelerate progress in this area, bringing help and answers to families and leading to increased scientific understanding of the neurobiology of Autism as a necessary step towards treatments.”

ASD Expertise of the Tute Genomics Team

Tute Genomics’ leadership team possesses leading expertise in ASD discovery. As a former researcher at the University of Utah, Dr. Robison conducted gene-finding studies in large extended pedigrees with ASD. He also has also been principal investigator for a number of early-stage clinical trials of novel therapeutics for ASD.

Kai Wang, Ph.D., President of Tute Genomics, has researched extensively the genetics of ASD and related psychiatric disorders. Dr. Wang led or participated in multiple copy number variation studies, genome-wide association studies and next-generation sequencing studies on ASD.

His study on common genetic variants associated with ASD, featured in a May 2009 issue of the journal Nature, was named one of Time magazine’s Top 10 Medical Breakthroughs of 2009.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Understanding Circulating Tumour Cells
Research team develops new tool to track traveling cancer cells in the bloodstream.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!